Verona Pharma
plc
("Verona Pharma" or the
"Company")
Change in
Registered Office
19 April 2016, Cardiff –
Verona Pharma plc (AIM: VRP.L), the drug development company
focused on first-in-class medicines to treat respiratory diseases,
today announces that its registered office address has changed to:
One Central Square, Cardiff, CF10 1FS.
For further information, please
contact:
Verona Pharma plc
Jan-Anders Karlsson, CEO |
Tel: +44 (0)20 7863 3300 |
|
|
N+1 Singer
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
|
|
FTI Consulting
Simon Conway / Julia Phillips |
Tel: +44 (0)20 3727 1000 |
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. In addition, the Company
is exploring the potential of the drug in different diseases, such
as cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the UK Cystic Fibrosis
Trust.